Business Wire

Teleroute, Part of Alpega Group, Confirms Robust Recovery of Freight Offers After Coronavirus Shock

Share

The activity registered on the Teleroute Freight Exchange has been experiencing an upward trend for several weeks following the strong increase in demand for their solution during the Coronavirus crisis, demonstrating the resilience and anti-cyclical nature of one of Europe’s leading freight exchanges.

After the initial shock to the European market due to the Coronavirus, the Teleroute Freight Exchange, that together with 123Cargo and Wtransnet form one of the largest European transport collaboration networks, confirms the return of activity with a notable upturn in the number of freight offers in recent weeks, placing the activity at pre-coronavirus level and even higher in the last weeks of July, exhibiting none of the typical seasonal slowdown.

The most difficult moment for the transportation industry due to the crisis took place in April, where the complete stoppage of industrial activity throughout Europe caused freight volume to drop dramatically. This period was then followed by a second disrupted supply chain period where freight forwarders and carriers, looking for new routes for new volumes, turned to Teleroute to manage demand and the number of new users on Teleroute grew by 1,200.

Speaking about this trend, Fabrice Douteaud, COO of Teleroute, said: “We are very proud of the resilience shown by the transport & freight forwarding companies by continuing their important work during these very difficult times. We have experienced an exceptional demand for our freight exchange during this crisis, a proof of the value we bring to the market: facilitating the collaboration of transport professionals.”

France, the driving force behind the recovery of freight offers in Europe

After the month of April with volume below average, we are in the middle of the summer with a very notable recovery of the freight offers on Teleroute with France as the country of origin, which has doubled.

This leaves us with an activity in July that has far exceeded the monthly average number of published freight offers, mainly in the domestic market (90% of volumes) and in exports to Belgium, Germany and Spain in equal parts.

On the other hand, if we look at imports, the numbers are even better, in the last two months we find volumes well above the usual and that shows the recovery of the main countries that send merchandise to France: Italy, which leads the ranking with 37% of freight offers; Germany (29%), Belgium (23%) and Spain (7%).

Italy doubles its transport activity in July thanks to exports

Regarding the data obtained from the freight offers published on Teleroute originating in Italy, one of the countries most affected by the pandemic, we find a surprising recovery in July where the volume has doubled thanks to the reactivation of transactions with France, which account for 57% of Italian exports. Germany with 18% and Spain with 15% close the top 3.

In relation to inbound freight, the transalpine country doubled the number of import offers in July compared to previous months, placing activity above the average in 2019 and only slightly lower than the months with the highest activity on the freight exchange. A comeback led by the flow of goods with France, with 40% of the freight offers published, and Germany (15%) as the main countries offering freight to the Italian market.

Huge growth in the German domestic transport market

Focusing on Germany, another of the European economy's main drivers, we observed a strong rebound in activity in July with 25% above the monthly average in 2019, the domestic market's upward growth, which was already palpable in June, and accounting for 50% of the freight offers with Germany as origin and/or destination.

The other freight offers, are divided into 28% imports, mainly from Italy and France, and exports (remaining 22%) whose main destinations are France and the Netherlands.

Numbers that, in accordance with the offers registered in Teleroute, place the European transport market that Teleroute serves, already back to normal in practically the entire region and, on the current trajectory, will be performing ahead of 2019 for the remainder of the year.

Alpega Group

End-to-End Transportation software

Alpega Group is a leading global logistics software company offering modular solutions that cover all transportation and logistics complexity needs. By bringing together the best solutions and market expertise, the Alpega Group has created the transportation industry’s only scalable end-to-end software suite.

Alpega TMS empowers transport professionals to manage the logistics and supply chain processes, it transforms global and local supply chains into collaborative ecosystems, bringing together all parties involved. Alpega TMS’s unique scalability and best-in-breed standalone solutions ensure shippers benefit from a system that evolves alongside their needs, regardless of the complexity of their logistics processes. Our freight procurement solution, TenderEasy, provides a world-class solution for sourcing transportation providers across air, land and sea. In terms of freight exchanges, 123Cargo, Teleroute and Wtransnet are leading European marketplaces designed to match spot shipments and truck capacity.

These platforms and the data which flows through them, alongside our 30+ years’ experience in transportation lets us enable businesses to optimize their supply chain planning and execution while benefitting from lower costs and higher visibility. All of Alpega’s solutions combine to create added value for customers. Our community of 80,000 carriers and 200,000 members are electronically connected every day to successfully manage critical transport processes. Alpega is present in 80 countries worldwide and employs 500 people with 31 different nationalities.

More information can be found at www.alpegagroup.com.

Contact information

Press
Verónica Rodríguez
Head of Brand & Communications, Alpega Group
veronica.rodriguez@alpegagroup.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ESMO 2020: Cabometyx ® (cabozantinib) in Combination With Opdivo ® (nivolumab) Demonstrates Significant Survival Benefits in Patients With Advanced Renal Cell Carcinoma in Pivotal Phase III CheckMate -9ER Trial19.9.2020 18:30:00 CESTPress release

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the first presentation of results from the pivotal Phase III CheckMate -9ER trial, in which Cabometyx® (cabozantinib) in combination with Bristol Myers Squibb’s Opdivo® (nivolumab) demonstrated significant improvements across all efficacy endpoints, including overall survival (OS), in previously untreated advanced renal cell carcinoma (RCC).1 Cabometyx® in combination with Opdivo® reduced the risk of death by 40% versus sunitinib (HR: 0.60 [98.89% Confidence Interval [CI]: 0.40–0.89]; p= 0.0010; median OS not reached in either arm). In patients receiving Cabometyx® in combination with Opdivo®, median progression-free survival (PFS), the trial’s primary endpoint, was doubled compared to those receiving sunitinib alone: 16.6 months versus 8.3 months respectively (Hazard Ratio [HR]: 0.51 [95% CI 0.41–0.64], p < 0.0001). In addition, Cabometyx® in combination with Opdivo® demonstrated a superior objective response rate, wit

Takeda Presents New Data Highlighting Scientific Advancements in Lung Cancer at ESMO Virtual Congress18.9.2020 12:55:00 CESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the company is presenting data from its lung cancer portfolio at the virtual European Society for Medical Oncology (ESMO) conference. Notably, insights from sub-analyses of the Phase 3 ALTA 1L study reinforce both the compelling evidence of intracranial efficacy with ALUNBRIG® (brigatinib) as a first-line treatment for patients with anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) as well as associated quality of life (QoL) data. Takeda is also featuring updated 10-month follow-up results from the Phase 1/2 trial of mobocertinib (TAK-788), demonstrating mobocertinib achieved a duration of response (DoR) of more than one year in the trial’s study population of patients with epidermal growth factor receptor (EGFR) Exon20 insertion+ metastatic NSCLC (mNSCLC). “We’re pleased to present our ongoing research in lung cancer at this year’s virtual ESMO congress, including new

Incyte Announces Encouraging Results From Phase 2 Trial of Retifanlimab (INCMGA0012) in Patients With Previously Treated, Advanced Squamous Cell Carcinoma of the Anal Canal18.9.2020 12:00:00 CESTPress release

Incyte (Nasdaq:INCY) today announced results from its Phase 2 POD1UM-202 trial evaluating retifanlimab, a PD-1 inhibitor, in previously treated patients with advanced squamous cell carcinoma of the anal canal (SCAC) who have progressed following standard platinum-based chemotherapy. The trial enrolled 94 patients, including those with well-controlled human immunodeficiency virus (HIV) infection (10%). Retifanlimab monotherapy resulted in a confirmed objective response rate (ORR) of 14% as determined by independent central review (ICR) using RECIST v1.1. Responses were observed regardless of PD-L1 status, presence of liver metastases, age or HIV+ status. Retifanlimab was generally well-tolerated with a safety profile as expected of a PD-1 inhibitor and no loss of HIV infection control. Key findings from POD1UM-202: N=94 ORR* (95% CI) 13.8% (7.6-22.5) Best OR*, n 1 CR 12 PR 33 SD DCR 48.9% DOR, median (95% CI), months 9.5 (5.6-NE) PFS, median (95% CI), months 2.3 (1.9-3.6) OS, median (95

Sigfox and Cube Infrastructure Managers Announce Major Partnership in IoT Infrastructure18.9.2020 09:30:00 CESTPress release

Sigfox, the global 0G network1 and cloud provider for industrial data, is proud to announce a new strategic alliance with Cube Infrastructure Managers (Cube), through the sale of its German 0G network to Cube. Sigfox has grown its 0G IoT services by rolling out 0G networks across 72 countries and regions, which was largely achieved with partners called Sigfox Operators. These operators are the owners of the 0G networks, which they operate as exclusive connectivity providers of Sigfox IoT services, offering worldwide connectivity to customers. The sale of the German network to Cube will allow Sigfox to finance its continued innovation efforts in data value extraction and improvements in cloud algorithms to reduce energy consumption and allow the implementation of even more cost-effective devices and sensors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200918005116/en/ Cube Infrastructure Managers, the European infrastructu

Sensorion successfully raises approximately €31 (US$ 36.5) million in an oversubscribed private placement to US and European investors18.9.2020 08:00:00 CESTPress release

Regulatory News: Not for release, publication or distribution, directly or indirectly, in or into the United States, Canada, Australia or Japan. This press release is not intended as an offer and is for informational purpose only Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN – the “Company”) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders announces today the success of its previously announced capital increase. The Company has placed 18,236,000 new ordinary shares with a nominal value of €0.10 each (the “New Shares”), for total gross proceeds of approximately € 31 million by means of an accelerated bookbuild offering to the benefit of categories of persons (the “Reserved Offering”). The issue price of the New Shares is €1.70 per share, representing a 3.5% discount to the weighted average share price on the day preceding the date on which the issuance price

Vifor Pharma Group Announces Successful Sale of OM Pharma18.9.2020 07:00:00 CESTPress release

Regulatory News: Vifor Pharma has today announced the successful sale of 100% of the share capital of OM Pharma, a Vifor Pharma Group company to Optimus Holding Ltd. The terms of the deal include: A purchase consideration of MCHF 435 for 100% of the share capital An earn out related to potential future value gains on 20% of Optimus Holding Ltd. equity to be determined before the end of 2027 upon a trade sale, IPO or EBITDA multiple This earn out together with the purchase consideration could result in a total transaction value exceeding MCHF 500. The deal is expected to close within 30 days. OM Pharma is a Geneva-based company mainly active in the field of microbial derived immunotherapeutics and has developed strongly outside the core strategy of Vifor Pharma over the past few years. Optimus Holding Ltd. is a Swiss Group, founded by Etienne Jornod together with long-standing Swiss entrepreneurs and Abdi Ibrahim (28.5%), a Turkey-based pharmaceutical company operating in 12 countries a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom